Jiangsu Hongweites Pharmaceutical Technology Co., Ltd.

Hongweitesi has always focused on the research and development, production and sales of new detection technologies and new in vitro diagnostic reagents. It is a "high-tech enterprise" certified by Jiangsu Province and has successively passed TUV EN ISO13485:2016, China Medical Device Huaguang (CMD) YY/T 0287-2017 idt IS 13485:2016, GB/T 19001-2016 idt ISO 9001:2015 and other certifications, as well as CE certification for some products. With a professional R&D, production and management operation team, the company currently has molecular diagnostics, immunity, POCT and other technology platforms, and its product lines cover business areas such as infectious disease prevention and control, reproductive health testing, genetic disease testing, personalized drug gene testing and COVID-19 testing. It has successively undertaken many projects such as the National Infectious Disease Special Project, the National High-tech Research and Development Plan (863 Plan), the National Key Basic Research and Development Plan (973 Plan), and the National Natural Foundation of China. It has established close scientific research cooperation relationships with the top domestic scientific research institutions and has obtained more than 20 national patents.